โ
๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ
โข Net sales: DKK 78.5B, +3% CER
โข Adjusted net sales: DKK 78.5B, +7% CER
โข Operating profit: DKK 27.1B, -16% CER
โข Adjusted operating profit: DKK 33.4B, +11% CER
โข Reported operating profit was impacted by a DKK 6.3B non-cash impairment charge related to pipeline assets, including monlunabant (DKK 4.0B)
โ
๐ฏ ๐๐ฎ๐ข๐๐๐ง๐๐
โข FY2026 adjusted sales growth raised to 0% to -6% CER
โข FY2026 adjusted operating profit growth raised to 0% to -6% CER
โข Improved outlook driven by stronger expectations for GLP-1 product sales
โ
๐ ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ
โข Wegovy pill surpassed 265,000 weekly US prescriptions and has exceeded 5 million prescriptions since launch
โข Wegovy pill launched in the UAE and UK, with additional market launches planned in the coming quarters
โข Wegovy HD launched in the US, while the 7.2 mg single-dose pen rollout across the EU is planned for H2 2026
โข EMA approved both Wegovy 7.2 mg single-dose pen and Wegovy pill in July
โข The Phase 3 ZEUS trial for ziltivekimab did not meet its primary endpoint
